<DOC>
	<DOCNO>NCT02844322</DOCNO>
	<brief_summary>The purpose study compare efficacy cyclophosphamide plus dexamethasone combine rituximab bortezomib regimens newly diagnose Waldenström macroglobulinemia patient .</brief_summary>
	<brief_title>The Comparison RCD Versus BCD Newly Diagnosed Waldenström Macroglobulinemia</brief_title>
	<detailed_description>Newly diagnose WM patient randomly assign BCD RCD group introduction chemotherapy . Chemotherapeutic response evaluate 3 cycle . If PR better response achieves , addition 3 cycle give . If , patient cross control group another 3 cycle . If PR better response come , addition 3 cycle give , otherwise , patient quit study .</detailed_description>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>1. age &gt; =18 year 2. diagnose LPL/WM 3. untreated mild treat without standard regimen , especially untreated rituximab and/or bortezomib 4. symptom patient 5. lifeexpectancy 3 month . 1. diagnosed malignancy outside BNHL within one year ( include active center neural system lymphoma ) 2. transform lymphoma 3. liver renal function lesion unrelated lymphoma 4. serious complication uncontrolled diabetes , gastric ulcer serious angiocardiopathy determine physician 5 . HIV positive active HBV infection uncontrolled systematic infection 6. clinical central nervous dysfunction 7. serious surgery within 30 day 8. pregnancy baby nursing period uncontracepted childbearing period woman ; 9. allergy trail drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>